Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 7Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Stomach Neoplasms 1Seminoma 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pelvic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Nervous System Neoplasms 1

Interventions

Paclitaxel 2pegfilgrastim 1Taxes 1Sunitinib 1Mental Status and Dementia Tests 1Lapatinib 1Ifosfamide 1Cisplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dysgerminoma × Sunitinib × Gynecologic × Clear all
NCT00453310 2015-10-27

Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
10 enrolled 6 charts
GenitourinaryGynecologic

Testicular Germ Cell Tumor, Dysgerminoma, Ovarian Neoplasms, Teratoma, Testicular Neoplasms, Carcinoma, Embryonal, Seminoma, Endodermal Sinus Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡